Inari recalled the catheter and revised instructions for use after reports of the device becoming entrapped or blocking patients’ lung arteries.
Inari updates label of clot removal device linked to 6 deaths Read More »
The 13-week program will offer funding and guidance to up to 12 health tech, medtech and biotech startups working on AI tools.
Johns Hopkins, CareFirst, Techstars launch healthcare AI accelerator Read More »
If all newly eligible patients received semaglutide, Medicare Part D spending could increase by $34 billion to $145 billion each year, according to new research.
Semaglutide coverage for weight loss could cost Medicare billions: study Read More »
The company announced Tuesday that despite the error preventing the analysis of late-stage results, the FDA confirmed that data from other completed trials are sufficient to support an NDA submission in the first quarter of 2025.
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error Read More »
Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.
Broken Deals: 4 Pharma Assets Returned to Biotech This Year Read More »
Massachusetts’ biopharma jobs increased 2.6% in 2023, according to the MassBio Industry Snapshot. Whether the state’s jobs grow in 2024 remains to be seen based on this year’s layoffs and seemingly slowed hiring based on BioSpace data.
Massachusetts’ Biopharma Jobs Grew at Slowed Rate in 2023: Report Read More »
With the FDA’s rejection of Ordspono in March, Monday’s green light from the European Commission marks the first approval worldwide and the first regulatory victory for Regeneron’s bispecific antibody platform.
Regeneron Scores EU Lymphoma Approval for Bispecific Antibody Ordspono Read More »
The number of patients who will be eligible for Novo Nordisk’s blockbuster GLP-1 under new Medicare Part D plan guidelines will vary depending on how cardiovascular disease is defined, according to researchers.
Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study Read More »
Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna’s Express Scripts is taking Humira off its major commercial formularies starting next year and focusing on more affordable biosimilar options.
Cigna to Remove AbbVie’s Humira from Formularies, Putting More Pressure on Blockbuster Read More »
Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase single-dose vials of Zepbound—without the autoinjector—at a 50% discount or more versus other incretin obesity treatments.
Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials Read More »
